Isomorphic Labs Raises $5B as Europe’s AI Drug Discovery Industry Faces Its Clinical Test

· · Views: 2,141 · ⏱ 3 min time to read

London-based Isomorphic Labs has raised $5 billion in Series C funding to advance artificial intelligence-designed medicines toward clinical trials, marking another major investment in Europe’s emerging AI biotechnology industry.

The November 17 financing announcement named Greenoaks and Sequoia Capital as co-lead investors, alongside Andreessen Horowitz and continued investment from Alphabet.

Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also participated.

The investment comes approximately six months after Isomorphic raised $2.1 billion in Series B financing, bringing the two rounds’ combined value to $7.1 billion.

But the larger question is whether increasingly sophisticated AI models can move beyond identifying promising molecules to producing medicines that demonstrate safety and effectiveness in humans.

From Protein Predictions to Drug Development

Founded in 2021 as a spinout from Google DeepMind, Isomorphic Labs is led by founder and CEO Sir Demis Hassabis and president Max Jaderberg.

Its central technology is IsoDDE, an AI drug-design engine that uses foundational simulation models to predict molecular behavior and refine potential medicines before laboratory testing.

The company says its systems can explore large chemical spaces and evaluate candidates across multiple therapeutic areas and drug modalities.

According to its announcement, Isomorphic has obtained encouraging preclinical results from internal oncology and immunology programs and work with pharmaceutical partners.

However, the company has not published detailed clinical evidence demonstrating that its internally developed medicines work in patients.

That distinction matters because predicting molecular properties is only one part of pharmaceutical development. Drug candidates must still undergo experimental testing, toxicology assessments and human trials before regulatory approval becomes possible.

Major Pharmaceutical Companies Join the Strategy

Isomorphic already works with pharmaceutical companies including Eli Lilly, Novartis and Johnson & Johnson.

Its partnerships with Lilly and Novartis were announced in 2024 with a combined potential value of approximately $3 billion, including milestone payments.

Johnson & Johnson joined its partner network in early 2026.

These agreements demonstrate commercial interest in AI-assisted drug design, although potential milestone values should not be confused with guaranteed revenue.

The company plans to use the latest financing to expand its drug pipeline, strengthen its AI systems and establish additional translational and clinical development infrastructure.

Hassabis said the investment would help advance the company’s first therapeutic programs toward clinical trials.

Europe’s AI Investment Shifts Toward Scientific Infrastructure

The financing illustrates the growing capital requirements of AI companies attempting to convert foundational research into commercially valuable scientific products.

Unlike conventional software businesses, AI drug developers must combine computing resources with experimental laboratories, specialist researchers, biological validation and regulated clinical development.

Isomorphic’s headquarters are in London, with additional operations in Cambridge, Massachusetts, and Lausanne, Switzerland.

Its latest investment round did not disclose a company valuation, meaning the financing amount cannot independently establish its market worth.

For European founders and investors, the development signals a potential shift toward AI businesses whose competitive advantages depend on proprietary scientific models, biological data and physical research infrastructure.

The next challenge is clinical validation.

If Isomorphic’s technology can consistently produce viable medicines, it could strengthen Europe’s position in AI-driven biotechnology. Until then, the funding remains a substantial investment in a scientific and commercial proposition that still requires decisive testing.

Share
f 𝕏 in
Copied